IBD patients on anti-TNF therapy showed significantly higher anti-S-IgG levels after previous SARS-CoV-2 infection (3410 AU/mL (1843–6617 AU/mL)) compared to patients on anti-TNF therapy without previous infection (8434 AU/mL (6227–20,155 AU/mL); p = 0.020) (Supplemental Figure S2). Here, TNF is linked to inflammatory bowel disease.